Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0017638 (
glioma
)
30,880
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Noncoding RNAs regulate transcription of gene expression and play an important role in the pathogenesis of glioblastomas. These tumors are heterogeneous with some
glioma
stem cells (GSCs) that are highly tumorigenic subpopulations of cells contributing to recurrence and treatment resistance. In this study, GSCs were established by neurosphere cultures of primary glioblastoma cells and validated by the expression of GSC marker CD133. The expression of the long noncoding RNA HOTAIRM1 was detected using real-time quantitative reverse transcription PCR (qRT-PCR). The role of HOTAIRM1 in the proliferation, apoptosis, stemness, and tumorigenicity of GSCs was investigated by soft agar colony formation, flow cytometry, TUNEL analysis, sphere formation, and in vivo xenograft models through silencing of HOTAIRM1. The expression of HOTAIRM1 and the neighboring HOX genes were analyzed by qRT-PCR in different grades of gliomas and nontumor tissues. We found that HOTAIRM1 is significantly elevated in GSCs. The silencing of HOTAIRM1 significantly impairs the proliferation, apoptosis, self-renewal, tumorigenesis of GSCs. In addition, HOTAIRM1 is significantly upregulated in gliomas and associated with tumor grade and patient survival. HOTAIRM1 neighboring genes, HOXA1,
HOXA2
, and HOXA3, are also significantly upregulated in gliomas and correlate with the expression of HOTAIRM1. Among them,
HOXA2
and HOXA3 were identified as being upregulated in GSCs and contributed to the self-renewal of these stem cells. Taken together, our results demonstrate that HOTAIRM1 plays a critical role in the self-renewal of GSCs. These data also suggest that overexpression of HOTAIRM1 can be a negative prognostic factor for patient survival in malignant
glioma
and may be a promising potential therapeutic target.
...
PMID:Long Noncoding RNA HOTAIRM1 Maintains Tumorigenicity of Glioblastoma Stem-Like Cells Through Regulation of HOX Gene Expression. 3169 Nov 27
In recent years, studies have revealed
HOXA2
as a new oncogene, but its function is unknown in gliomas. We aimed to reveal the relationship between
HOXA2
and
glioma
based on the Chinese
Glioma
Genome Atlas(CGGA) and the cancer genome atlas (TCGA).
HOXA2
expression data and clinically relevant information of
glioma
patients were obtained from the CGGA and TCGA containing 1447
glioma
tissues and five non-tumor brain tissues. The Wilcox or Kruskal tests were used to detect the correlation between the
HOXA2
expression level and clinical data of
glioma
patients. the Kaplan-Meier method were used to examine the relationship between
HOXA2
and overall patient survival. Gene set enrichment analysis (GSEA) was conducted to indirectly reveal the signaling pathways involved in
HOXA2
, and RT-PCR was used to detect
HOXA2
expression in gliomas and non-tumor brain tissues. High
HOXA2
expression was found to be positively correlated with clinical grade, histological type, age, and tumor recurrence, but negatively correlated with 1p19 codeletion and isocitrate dehydrogenase mutation status.RT-PCR results showed that
HOXA2
expression levels were significantly higher in tumor tissues than in non-tumor brain tissues. GSEA showed that
HOXA2
promoted the activation of the activation of the JAK-STAT-signaling pathway, focal adhesion, cell-adhesion-molecules-CAMS pathway, cytosolic DNA sensing pathway, and natural killer cell-mediated cytotoxicity. This study revealed for the first time that the novel oncogene,
HOXA2
, leads to poor prognosis in gliomas, and can be used as a biomarker for the diagnosis and treatment of gliomas.
...
PMID:Abnormally high expression of HOXA2 as an independent factor for poor prognosis in glioma patients. 3243 4